Related Experiment Video
Updated: Oct 5, 2025
Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
Published on: February 14, 2025
Advancement of chimeric antigen receptor-natural killer cells targeting hepatocellular carcinoma
1Department of Infectious Diseases, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei Province, China. daikai@whu.edu.cn.
Abstract:
With the advance of genome engineering technology, chimeric antigen receptors (CARs)-based immunotherapy has become an emerging therapeutic strategy for tumors. Although initially designed for T cells in tumor immunotherapy, CARs have been exploited to modify the function of natural killer (NK) cells against a variety of tumors, including hepatocellular carcinoma (HCC). CAR-NK cells have the potential to sufficiently kill tumor antigen-expressing HCC cells, independent of major histocompatibility complex matching or prior priming. In this review, we summarize the recent advances in genetic engineering of CAR-NK cells against HCC and discuss the current challenges and prospects of CAR-NK cells as a revolutionary cellular immunotherapy against HCC.
Insights
Chimeric antigen receptor (CAR)-Natural Killer (NK) cells show promise for treating hepatocellular carcinoma (HCC). This immunotherapy approach engineers NK cells to target and destroy HCC tumors, offering a novel therapeutic strategy.
Area of Science:
- Immunotherapy
- Oncology
- Genetic Engineering
Background:
- Chimeric antigen receptors (CARs) are advancing tumor immunotherapy.
- CARs are being engineered into Natural Killer (NK) cells for cancer treatment.
- Hepatocellular carcinoma (HCC) is a target for CAR-NK cell therapy.
Purpose of the Study:
- To review recent advances in genetic engineering of CAR-NK cells for HCC.
- To discuss the potential of CAR-NK cells as a cellular immunotherapy for HCC.
- To explore current challenges and future prospects of CAR-NK cell therapy in HCC.
Main Methods:
- Review of recent scientific literature on CAR-NK cell engineering.
- Analysis of CAR-NK cell efficacy against HCC tumor models.
- Discussion of genetic engineering strategies for CAR-NK cells.
Main Results:
- CAR-NK cells demonstrate potential to kill HCC cells expressing specific antigens.
- CAR-NK cell therapy is independent of major histocompatibility complex (MHC) matching.
- CAR-NK cells do not require prior priming for anti-tumor activity.
Conclusions:
- CAR-NK cells represent a promising immunotherapy for hepatocellular carcinoma.
- Genetic engineering of CAR-NK cells offers a novel strategy against HCC.
- Further research is needed to address challenges and optimize CAR-NK cell therapy for HCC.
